IGF-1 LR3

Overview

IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is a synthetic, modified analogue of human IGF-1 developed in the late 1980s and early 1990s by researchers at Australian biotechnology company GroPep (Ballard, Francis, and Tomas). Two deliberate modifications (an arginine substitution at position 3 (Arg3) and a 13-amino acid N-terminal extension peptide ("Long")) were engineered to prevent the peptide from binding to IGF-Binding Proteins (IGFBPs), dramatically extending its potency and duration of action compared to native IGF-1 [1][2].

In normal human physiology, over 98% of circulating IGF-1 is bound by IGFBPs (predominantly IGFBP-3), which restrict its activity and limit its half-life to roughly 20 minutes. LR3's modifications abolish this binding, allowing virtually 100% of the injected peptide to remain free and biologically active, extending its effective half-life to approximately 20–30 hours [3].

Its legitimate, primary commercial application is as a highly potent growth factor supplement for industrial mammalian cell culture (specifically biopharmaceutical manufacturing of monoclonal antibodies using CHO cells). It is also sold to the research market in multiple purity grades (Standard, Media Grade, Receptor Grade). IGF-1 LR3 was never approved for human use and never advanced past preclinical testing due to an insurmountable safety barrier identified in animal models [3].

Research Areas and Claims

IGF-1 LR3's published evidence base is entirely preclinical (rats and pigs). Common off-label claims in performance and wellness markets extend far beyond what the animal data supports, and well beyond any human trial evidence, which does not exist.

• Anabolic Potency in Animal Models: LR3 significantly outperforms native IGF-1 for nitrogen retention and protein synthesis in rats and growing pigs. Its IGFBP-evading design was proven effective in the species it was tested in [1][2].

• Biopharmaceutical Cell Culture: The primary industrial application: IGF-1 LR3 is a well-established, commercially validated growth supplement for mammalian cell culture (e.g., CHO cell lines used to produce monoclonal antibodies). This is its best-documented and scientifically legitimate use [3].

• Muscle Wasting Prevention (Preclinical): In glucocorticoid-treated rats, LR3 variants were significantly more effective than native IGF-1 at preventing muscle wasting, minimizing weight loss, and retaining nitrogen. Effect demonstrated via SC infusion over 7 days [1].

• Muscle Hyperplasia, Fat Loss, Recovery (Off-label Claims): Common performance-market claims: "new muscle cells," accelerated fat loss, injury recovery, derived entirely from extrapolating animal data and IGF-1R signaling theory to humans. No human trials exist to validate these claims for IGF-1 LR3 specifically.

Mechanism of Action

1. IGF-1R Binding & Receptor Activation: LR3 binds directly to the Type 1 IGF Receptor (IGF-1R) on target cells (muscle, bone, cartilage). Binding triggers receptor autophosphorylation and activates the PI3K/Akt and MAPK downstream signaling cascades, promoting cellular proliferation, anti-apoptosis, and protein synthesis [1][3].
2. IGFBP Evasion: Extended Half-life: The "Long" N-terminal extension and Arg3 substitution abolish affinity for all naturally occurring IGFBPs. In normal physiology, 98%+ of circulating IGF-1 is bound and inactivated by IGFBPs. LR3 bypasses this regulatory system entirely, remaining free and active in circulation for 20–30 hours versus the ~20-minute half-life of native IGF-1 [3].
3. Insulin Receptor Cross-Reactivity (Safety-Critical): Because of its structural similarity to insulin and its persistent free concentration, IGF-1 LR3 at higher doses binds to insulin receptors in addition to IGF-1Rs. This insulin receptor cross-activation mimics a massive insulin overdose, the primary mechanism behind the severe, acute hypoglycemia observed in preclinical models that halted human development [4].

Preclinical Evidence

IGF-1 LR3 has no human clinical trial data. All published efficacy evidence comes from preclinical animal models. Development was halted before Phase I human trials due to safety findings in animal pharmacology studies.

Administration Methods

• Subcutaneous (SC) / Intramuscular (IM): The routes used in in vivo animal studies and in off-label bodybuilding or clinic environments. Doses used in off-label settings are typically in the micrograms range (20–50 mcg) given its extreme potency, a fraction of the milligram-scale dosing typical of other research peptides.
• In Vitro (Cell Culture): The primary, scientifically validated use for IGF-1 LR3. Added to mammalian cell culture media (CHO cells, etc.) for biopharmaceutical manufacturing. Receptor Grade purity is specified for this application.
• Nasal Spray: Available from at least one vendor (Pure Rawz) as a pre-mixed solution. Mucosal bioavailability for this peptide via the intranasal route has not been established in published pharmacokinetic studies.

Vendor Directory

Data collected February 2026 via independent web search. No Finnrick vendor ratings exist for IGF-1 LR3. Tables split by grade and formulation route.

SC Injection: Standard / Unspecified Grade

* Peptide Sciences bulk discounts: buy 3 @ $105/ea; buy 5 @ $100/ea.

SC Injection: Media Grade

SC Injection: Receptor Grade

* Biotech Peptides bulk: 5–9 units $137.75/ea; 10+ $130.50/ea. Core Peptides bulk: 5–8 units $142.50/ea; 9+ $135.00/ea. Kit format rows (Peptide Sciences, Pure Rawz) contain 10 pre-measured 100 mcg vials totaling 1 mg.

Nasal Spray: Pre-Mixed Solution (Pure Rawz)

Combo / Blend Products (Behemoth Labz)

* Data Notes: Data collected February 2026 via independent web search. No Finnrick vendor list exists for IGF-1 LR3. All products sold strictly for in-vitro research purposes. Prices subject to change. $/mg calculated from listed catalog price divided by total mg per unit. Combo product $/mg reflects total peptide weight; individual component ratios are proprietary and not disclosed by Behemoth Labz.